日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Comprehensive analysis of FGFR2b and its correlation with essential biomarkers, intratumoral heterogeneity, and survival in advanced gastric cancer

对FGFR2b及其与晚期胃癌关键生物标志物、肿瘤内异质性和生存率的相关性进行全面分析

Kwak, Yoonjin; Kim, Tae-Yong; Lee, Hye Seung; Nam, Soo Kyung; Oh, Hyeon Jeong; Oh, Do-Youn; Im, Seock-Ah

Surface Modification of Cranioplasty Implants to Reduce Postoperative Cerebrospinal Fluid Collection: A Preliminary Clinical Study

颅骨成形术植入物表面改性以减少术后脑脊液积聚:一项初步临床研究

Kim, Tae Yong; Lee, Min Ho

Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression

法德拉西利(Fadraciclib)是一种 CDK2/CDK9 抑制剂,在胆道癌中显示出疗效,并且基于 MCL1 表达,与奥拉帕尼(olaparib)和 JQ1 具有协同作用的潜力。

Kim, Jae-Min; Nam, Ah-Rong; Oh, Kyoung-Seok; Bang, Ju-Hee; Jeong, Yoojin; Choo, Sea Young; Kim, Hyo Jung; Lee, Su In; Yoon, Jeesun; Kim, Tae-Yong; Oh, Do-Youn

Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma.

BOLD-100(一种 GRP78 抑制剂)在胰腺导管腺癌中的治疗潜力可通过 ATR 抑制而增强

Lee Su In, Nam Ah-Rong, Oh Kyoung-Seok, Kim Jae-Min, Bang Ju-Hee, Jeong Yoojin, Choo Sea Young, Kim Hyo Jung, Yoon Jeesun, Kim Tae-Yong, Oh Do-Youn

Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models.

建立和表征 24 个乳腺癌细胞系和 3 个乳腺癌类器官,揭示了恶性胸腔积液衍生模型中的分子异质性和药物反应变异性

Kim Soon-Chan, Kim Ga-Hye, Park Jae-Hyeon, Lee Kyung-Hun, Koh Jiwon, Kim Tae-Yong, Lee Dae-Won, Kim Yu-Jin, Kim Seongyeong, Park Song-Yi, Min Ahrum, Shin Young-Kyoung, Im Seock-Ah, Ku Ja-Lok

Comparative Colonisation Ability of Human Faecal Microbiome Transplantation Strategies in Murine Models

人类粪便微生物组移植策略在小鼠模型中的定植能力比较

Gu, Bon-Hee; Jung, Ho Young; Rim, Chae-Yun; Kim, Tae-Yong; Lee, Sang-Jin; Choi, Doo Young; Park, Han-Ki; Kim, Myunghoo

Unstimulated Highly Sensitive Thyroglobulin <0.2 ng/mL: Insufficient to Predict Stimulated Thyroglobulin <1 ng/mL?

未刺激状态下高敏甲状腺球蛋白<0.2 ng/mL:不足以预测刺激状态下甲状腺球蛋白<1 ng/mL?

Kim, Tae Yong

2025 Korean Thyroid Association Management Guidelines for Radioactive Iodine Therapy in Patients with Hyperthyroidism

2025年韩国甲状腺协会甲状腺功能亢进症患者放射性碘治疗管理指南

Kim, Kyeong Jin; Song, Eyun; Kim, Mijin; Kwon, Hyemi; Ku, Eu Jeong; Kwon, Hyun Woo; Yoon, Jee Hee; Lee, Eun Kyung; Lee, Won Woo; Park, Young Joo; Lim, Dong-Jun; Kim, Sun Wook; Kang, Ho-Cheol; Chung, Jae Hoon; Kim, Tae Yong; Kim, Sin Gon; Na, Dong Gyu; Kim, Jee Soo

Prognostic Impact of Primary Tumor Size in Papillary Thyroid Carcinoma without Lymph Node Metastasis

原发肿瘤大小对无淋巴结转移的乳头状甲状腺癌预后的影响

Kim, Chae A; Kim, Hye In; Kim, Na Hyun; Kim, Tae Yong; Kim, Won Bae; Chung, Jae Hoon; Jeon, Min Ji; Kim, Tae Hyuk; Kim, Sun Wook; Kim, Won Gu

Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression

对表达 Claudin 18.2 的 II-IV 期胃癌进行临床病理学和分子特征分析

Kwak, Yoonjin; Kim, Tae-Yong; Nam, Soo Kyung; Hwang, Hye Jung; Han, Daeyoung; Oh, Hyeon Jeong; Kong, Seong-Ho; Park, Do Joong; Oh, Do-Youn; Lee, Hyuk-Joon; Im, Seock-Ah; Yang, Han-Kwang; Lee, Hye Seung